Merck puts money on Arcoxia
Merck raises 2007 earnings guidance on the assumption that Arcoxia (etoricoxib), its follow-on product to the withdrawn arthritis medication Vioxx, will be approved by FDA, the company announces Dec. 6. The Arcoxia NDA has a user fee action date in April 2007 following Merck's submission of a response to FDA's November 2004 "approvable" letter (1"The Pink Sheet" Nov. 13, 2006, In Brief). The submission limits the proposed indication for the COX-2 inhibitor, which has been approvable since October 2004, to osteoarthritis. Merck anticipates that 2007 earnings per share will be in the range of $2.36 to $2.49. "Other sales," which includes products Arcoxia, Januvia and Proscar among many others, is expected to be between $5.2 billion and $5.6 bil...
You may also be interested in...
The European Commission has reluctantly allowed virtual audits in the context of new MDR and IVDR. The EU notified body association is helping the collective effort to meet its strict requirements.
The UK’s implementation of a new national licensing framework for biosimilars has been pushed back from the start of 2021, with the MHRA citing “intense COVID-19 activities” as the cause of an indefinite delay in the consultation process.
Hikma has temporarily stopped the roll-out of its rival to Advair Diskus in the US after it filed an amendment to its ANDA over packaging controls.